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Available online 21 September 2018Background: Aim of this study was to evaluate peri-procedural incidence of new diffusion-weighted-magnetic-
resonance-imaging (DWMRI) brain lesions in CAS patients treated by carotid mesh stent (CGuard™) or
closed-cell stent (Wallstent™).
Methods: Consecutive patients with asymptomatic carotid stenosis ≥ 70% were submitted to preoperative DW-
MRI scan, to exclude the presence of preoperative silent cerebral lesions. Patients were randomized to CGuard
or Wallstent. DWMRI was performed immediately after the intervention and at 72-hour postoperatively. More-
over, pre and postoperativeMini-Mental-State-Examination Test (MMSE) and aMontreal-Cognitive-Assessment
(MoCA) test were conducted, and S100β and NSE neurobiomarkers were measured at 5-time points (preopera-
tively, 2, 12, 24, and 48 h postoperatively).
Results: From January 2015 to October 2016, sixty-one consecutive eligible patients were submitted to preoper-
ative DWMRI scan. Three patients were excluded because of preoperative silent cerebral lesions. In 29 CGuard
patients, 1 developed aminor stroke and 8 silent new lesionswere observed in the 72 h-DWMRI (31%): 4 lesions
were ipsilateral, and 4 lesions were contra or bilateral. In 29 Wallstent patients, 7 clinically-silent new lesions
were found in the 72 h-DWMRI (24.1%; p = 0.38). In 4 cases lesions were ipsilateral and in 3 cases contra or
bilateral. S100B values doubled at 48 h in 24 patients, and among them 12 presented new DWMRI lesions.
48-h S100B increase was significantly related to 72-h DWMRI lesions (p = 0.012).
Conclusions: In our experience both stents showed an acceptable rate of subclinical neurological events with no
significant differences at 72-hour DWMRI between groups. Bilateral/contralateral lesions suggest that
periprocedural neurological damage may have extra-carotid sources.ccia),
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Brain ischemic lesion1. Introduction
1.1. Background
Stroke is one of the most frequent causes of death and morbidity
worldwide. Atherosclerotic stenosis of the extracranial internal carotid
artery has been invoked as a common causative factor for stroke in
over 20% of patients [1]. Although medical therapy can help to prevent
the onset and progression of carotid arteriosclerosis, open surgicalniroma1.it
si@uniroma1.it
and freedom from bias
an open access article undercarotid endarterectomy (CEA) has been the gold standard for treating
severe blockage. Alternatively, carotid stent angioplasty (CAS) has
been shown to protect patients from future stroke with long-term
efficacy similar to CEA [2]. In this context, carotid artery stenting has
been shown to be associated with a reduction in the risk of myocardial
infarction in high-risk surgical subgroups [2–4]. Nevertheless, it has
been considered that the main CAS limitation vs CEA is the relatively
superior incidence on clinical stroke [2] (most frequently minor). To
study this phenomenon, diffusion-weighted-magnetic-resonance-
imaging (DW-MRI) in asymptomatic patients after CAS has demon-
strated the incidence of more new cerebral lesions in CAS than in CEA
[3]. Likewise, some studies have reported increased level of specific
neurobiomarkers following carotid revascularization procedures, in
accordance to possible brain embolic events [5,6]. New and improved
procedural Embolic Protection Systems (including filters, proximal
protection flow-reversal and Trans Carotid Artery Revascularization
(TCAR)) has demonstrated neuroprotection in CAS peri-proceduralthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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procedural period a significant portion of the neurologic events may
occur (between 1 and 30 days following the stent implantation). This
observation suggests mechanisms such as plaque embolization through
the stent struts may occur [8]. In the symptomatic population late
complication rates are highest for the open cell types and increase
with larger free cell area [9], but despite the increasing use of closed-
cell design stents the risk of plaque prolapse through the stent struts
and of post-procedural embolism still exists [10]. In order to prevent
plaque prolapse, a new stent design has been conceived: CGuard com-
bines the traditional open-cell stent design to an exterior polyethylene
terephthalate (PET) mesh that is able to capture and keep in place
plaque debris as small as 150–180 μm. CGuard™ has demonstrated
post-procedural neuro protection, by reducing new lesions incidence
and volume at 1-month FU DWMRI (post-procedural) [11].
The first published prospective studies on the use of CGuard™ stent,
the CARENET [11] (Carotid Embolic Protection Using MicroNet) Trial
and the PARADIGM [12] Study have shown 0% MACNE (Major Adverse
Cardiac or Neurologic Events) at 30-days. The routine per-protocol
diffusion-weighted magnetic resonance cerebral imaging (DW-MRI)
demonstrated post-procedural embolic prevention efficacy. The
CARENET DW-MRI showed a low incidence of any ipsilateral new lesion
(s) (37%) after CAS and a very low average lesion volume (≈0.04 cm3)
[11], suggesting N50% reduction in incidence and N10-fold reduction in
mean lesion volume when compared to conventional carotid stents
[13,14]. Routine thirty-day DW-MRI imaging in CARENET revealed only
one small new lesion (0.08 cm3) and showed complete resolution of all
but one peri-procedural lesion [11].
So, if CGuard is protective post-procedurally, never has been
previously analyzed the hypothesis that CGuard may be preventive
during the peri-procedural period, from the cerebral filters removal up to
3 days postprocedurally, when the carotid plaque may be considered
most destabilized by the stent struts apposition and more prone to
embolize. Some studies have demonstrated that specific neurobiomarkers
are released into circulating blood whenever a brain insult occur [5,6].
Some of them can be detected within fewminutes from the neurological
ischemic event [15–19] so that their variation in time canhelpmonitoring
different phases of a single brain ischemia or multiple occurrences
of infracentimetric ischemic insults, as it can sometimes occur during or
after carotid revascularization. Moreover, cognitive performance varia-
tions can sometimes be observed after multiple microembolic ischemic
brain insults [20]. The aim of the present study is to determine the peri-
procedural incidence of new DWMRI brain lesions, neuropsychometric
tests conversion and neurobiomarkers appraisal, comparing a carotid
mesh stent (CGuard™) versus a control group treated with a carotid
closed cell stent (Wallstent™). Primary outcome was new DW-MRI
lesions in the two randomized stent groups. Secondary end-points were
the variation in neuropsychometric test (NPT) scores, and appraisal of
neurobiomarkers.
2. Methods
2.1. Trial design
Single-center, randomized controlled trial comparing results between two different ca-
rotid stents in patients affected by asymptomatic ≥ 70% carotid artery stenosis and submitted
to CAS in accordance with the ICCS-SPREAD Joint Committee consensus [21]. The present
study has been registered on ClinicalTrials.gov (NCT02665585).
2.2. Participants
CAS inclusion criteria were: age N 55 years, presence of a carotid stenosis ≥ 70%
(NASCET [22] evaluation criteria), with no previous neurologic symptoms referred in
the medical history, absence of a previous brain ischemic lesion detected at diffusion-
weighted-magnetic-resonance-imaging (DW-MRI). Patients with symptomatic carotid
lesions, previous ischemic lesions detected at DW-MRI, or inability to give consent were
excluded from the study.
Exclusion criteria for CASwere: significant contraindications to angiography, history of
bleeding disorder, or intracranial aneurysm or vascular malformation or hemorrhage,presence of intraluminal thrombus, poor entry points at the femoral artery, type 2–3 arch,
bovine arch, severe aortic arch or ipsilateral ostial common carotid or brachiocephalic
atherosclerosis, severe proximal commonor distal internal carotid artery tortuosity, sharply
angulated internal carotid artery, carotid string sign, circumferential calcification of carotid
plaque, length of the target lesion requiring more than one stent at contrast-enhanced CT
scans.
Eligibility criteria for randomization were: obtained informed consent, compliance to
the study protocol. Patients were randomized to receive either carotid Wallstent (Boston
Scientific,Marlborough,MA, USA)or C-Guard carotid stent (Inspire-MD, Boston,MA, USA)
a new mesh-covered open-cell stent. Written informed consent was obtained
before enrollment. The study protocol and informed consent form were approved by the
Institutional Ethical Committee.
2.3. Setting
All procedures were performed at the same center with an adequate annual volume
experience of the operators [23,24]. Data were collected and analyzed at our Vascular
Unit Academic Centre.
2.4. Interventions
Dual antiplatelet therapy was started at least three days before intervention and
maintained for at least 1 month post-procedurally. Single antiplatelet therapy was
maintained indefinitely. CAS intervention was performed under local anesthesia with a
distal embolic protection device in all cases (Filterwire, Boston Scientific, Marlborough,
MA, USA). Wallstent or CGuard stent were alternatively used to cover the whole plaque
surface. No predilatation was used in the present series.
2.5. Diffusion-weighted magnetic resonance imaging (DWMRI) performance
All patients were submitted to preoperative, immediate postoperative (from 30 min
to 1-hour), and 72 h DW-MRI. A comparison between immediate postoperative and
72-hour examinations was performed in order to detect any off-table events. Presence
of recent ischemic lesions at preoperative examination was considered an exclusion
criterion for entering the study.
2.6. Mini-Mental State Examination (MMSE) test and Montreal Cognitive Assessment (MoCA)
test administration and interpretation
All patients were submitted to preoperative and 72-hour postoperative MMSE
and MoCA tests in order to prove the effect of CAS-related microemboli on cognitive per-
formance. The research assistant responsible for performing the tests preoperatively and
postoperatively in all patients was trained to administer and score the tests. Downgrading
in the postoperative examination, such as from normal to some cognitive impairment
(1 step), or a difference ≥ 4 in the postoperative score compared with the preoperative
value, was considered significant. No psychotropic or sedative medications were adminis-
tered to the patients before performing tests.
2.7. Neuron-Specific Enolase - NSE and S100β serum levels detection and analysis
The S100 test measures the β-subunit of protein S100 as defined by threemonoclonal
antibodies with a detection limit of 0.02 μg/L. NSE measurement is based on monoclonal
antibodies that bind to the γ-subunit of the enzyme with a minimal measurable concen-
tration of 0.3 μg/L. S100β and NSE proteins were analyzed by the use of automated
immunoluminometric assays (S100 Elecsys test, Roche Diagnostics GmbH, Mannheim,
Germany; ELSA-NSE, CIS Bio International, Gif-sur-Yvette Cedex, France). Venous blood
samples were obtained for each patient preoperatively (basal sample), and at 2, 12, 24,
and 48 h after the end of the procedure. Sampleswere allowed to clot. After centrifugation
(1800g for 6 min) ≤20min from collection, serum was stored at−80 °C for later analysis.
2.8. Objective
To demonstrate a decrease in off-table microembolic event rate in patients submitted
to CASwith CGuard stent implantation compared to patients withWallstent implantation,
detected by DW-MRI, markers of brain injury, and neuropsychometric tests.
2.9. Outcome measures
Primary outcome measures considered for comparative analysis in the two CAS groups
were perioperative off-table (up to 72 h postoperatively) neurological ischemic events
clinically (TIA, stroke, permanent focal retinal artery occlusion, neurological death) or
subclinically detected (by new DW-MRI lesions).
Secondary outcomes measures were perioperative (up to 72 h postoperatively)
≥0.02 μg/L increase in S100β and/or ≥0.3 μg/L increase in NSE serum levels, ≥5 variation
in postprocedural MMSE test score or MoCA test score compared to the preoperative one
in the two treatment groups, rate of perioperative local complications (inguinal
haematoma, pseudoaneurysm formation, access vessel dissection or thrombosis) or
systemic complications (acutemyocardial infarction (AMI) detected bymyocardial specific
enzymes increase and electrocardiographic alterations, transient or permanent renal
impairment defined as a creatinine serum level increase ≥ 25% of the basal value, ≥24 h
Table 1
Baseline features in 29 CGuard patients and 29 Wallstent patients.
CGuard Wallstent P
(OR; 95%CI)
Age (mean ± SD; 95%CI) 70.4 ± 5.91
(66.86–73.94)
68.8 ± 7.43
(65.12–72.45)
0.52
Male sex (n;%) 20 (68.9%) 22 (75.8%) 0.55
(0.70; 0.22–2.25)
Right side (n;%) 19 (65.5%) 12 (41.4%) 0.06
(2.69; 0.92–7.8)
Smoke (n;%) 14 (48.3%) 19 (65.5%) 0.18
(0.49; 0.17–1.41)
Hypertension (n;%) 27 (93.1%) 26 (89.6%) 0.62
(1.55; 0.24–10.09)
Dyslipidemia (n;%) 26 (89.6%) 28 (96.5%) 0.30
(0.31; 0.03–3.16)
Diabetes (n;%) 11 (37.9%) 5 (17.2%) 0.07
(2.83; 0.86–9.94)
150 L. Capoccia et al. / International Journal of Cardiology 279 (2019) 148–153hypotension or bradycardia, respectively defined as systolic blood pressure ≤ 120mmHg, and
heart rate ≤ 60 bpm, acute respiratory failure requiring prolonged orotracheal intubation).
2.10. Statistical analysis
2.10.1. Sample size estimation
Data from previously published study demonstrated an extremely variable incidence
of DWMRI-detected brain microembolism [25]. Based on our experience [5], we consid-
ered an incidence of around 40% inpatients submitted to CASwithWallstent implantation.
No data are available on 72-hours brain embolism in patients submitted to CGuard
implantation, so we speculated a subclinical incidence of neurological events of 10%. We
considered a new event any ischemic lesion detected by DWMRI, independently from
number or size of lesions recorded. Assuming a type I error α= 0.05, a type II error β=
0.20, so a power (1-β) = 0.80, an event rate in the control (Wallstent) group of 0.40
(40%) [5], an event rate in the treatment (CGuard) group of 0.10 (10%), so assuming a
30% event rate reduction in the treatment group, 29 patients were randomly allocated in
each treatment group.
2.10.2. Randomization
A computer-generated random allocation sequence was used. A blocked randomiza-
tion was performed with an allocation ratio 1:1. Allocation concealment was used. Blind
postprocedural DW-MRI interpretation, neurobiomarkers levels evaluation, and MMSE
and MOCA administration was done by those assessing outcomes.
2.10.3. Results analysis
Categorical variables are reported as numbers and percentages and compared by
Fisher and chi-square tests. Continuous data are reported as median and standard devia-
tion and compared by s-Student test andANOVA formultiple samples. Analysis of variance
has been used to test the differences among and between groups at different time-points.
Moreover, neurobiomarker values have been categorized as follows and analyzed as
categorical variables: in every patient variations of S100B and NSE have been analyzed
comparing every value with the basal one and the 48-hour value with the basal one, so
that every patient has been classified twice as belonging to “increased”, “stable”, or
“decreased” category if a ≥25% variation was detected. NPTs scores were analyzed as
continuous values and also categorized and analyzed if a ≥4 increase or decrease between
two consecutive assessments was detected.
3. Results
From January 2015 to October 2016 fifty-eight patients were
randomized at our Academic Center. Three patients were excluded from
the study before randomization because of the presence of preoperative
DWMRI clinically silent lesions (Fig. 1). Technical success was 100%.Fig. 1. Peri-procedural brain lesions prevention In CAS (3PCAS)Postdilatation was used in 86.2% of patients. Baseline and procedural
features are reported in Tables 1 and 2.
In 29CGuard patients 1minor stroke (ipsilateral lesion) and 8 clinically
silent 72 h-DWMRI lesions detections were recorded (31%), and in 29
Wallstent patients 7 clinically silent 72 h-DWMRI lesions detections
were found (24.1%; no statistically significant difference between the
two treatment groups; p = 0.38; Table 3).
Two patients presented with immediate postoperative DWMRI
lesions. Interestingly, those lesions were no longer detectable at 72 h
DWMRI control. According to the site of DWMRI lesions, in 8 CGuard
patients 4 had ipsilateral, and 4 contra or bilateral lesions. In 7Wallstent
patients 4 had ipsilateral and 3 contra or bilateral lesions. Mean
DWMRI lesion diameter was 3.87 ± 1.53 mm (95%CI 3.307–4.436)
in CGuard group and 3.56 ± 1.07 mm (95%CI 2.871–4.253) in
Wallstent group (p = 0.49; Table 3). Five or more DWMRI lesions
were detected in 5 CGuard patients and in 3 Wallstent patients (p =
0.5). No significant associationwas encounteredwith stent postdilatation
in patients presenting postoperative DWMRI lesions (p = 0.46).
Within group analysis of neuropsychometric tests (NPTs) showed a
significantly better postoperative MoCA score in Wallstent patientsrandomized controlled trial randomization flow diagram.
Table 2
Carotid lesion and procedure features in 29 CGuard patients and 29 Wallstent patients.
CGuard Wallstent P
(OR; 95%CI)
Stenosis percentage (mean ± SD; 95%CI) 78.7 ± 7.19
(74.81–82.53)
78.9 ± 7.38
(74.93–82.92)
0.92
Femoral access (n;%) 29 (100%) 29 (100%) 1
Distal embolic protection device (n;%) 29 (100%) 29 (100%) 1
Predilatation (n;%) 11 (37.9%) 5 (17.2%) 0.07
(2.93; 0.86–9.94)
Postdilatation (n;%) 22 (75.8%) 19 (65.5%) 0.38
(1.65; 0.52–5.19)
Procedural time (minutes; mean ± SD; 95%CI) 23.7 ± 2.53
(21.89–25.45)
25.6 ± 4.07
(23.73–27.41)
0.14
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analysis of postoperative scores in both groups showed not significant
better scores in Wallstent patients (p = 0.12 and p = 0.45 for MMSE
and MoCA, respectively; Table 3). NPTs postoperative scores showed
a significant association with the presence of N5 DWMRI lesions,Table 3
Outcomes in 29 CGuard patients and 29 Wallstent patients.
CGuard
Positive 72 h-DWMRI (n;%) 9 (31%)
72 h-DWMRI lesion number per pt
(mean ± SD; 95%CI)
3.56 ± 2.30
(2.05–5.06)
72 h-DWMRI lesion diameter
(mean ± SD; 95%CI)
3.87 ± 1.53
(3.3–4.43)
Preprocedural MMSE
(mean ± SD; 95%CI)
27.9 ± 3.23
(26.16–29.56)
Postprocedural MMSE
(mean ± SD; 95%CI)
26.8 ± 2.42
(25.66–27.96)
Preprocedural MoCA
(mean ± SD; 95%CI)
22.9 ± 4.88
(19.86–25.91)
Postprocedural MoCA
(mean ± SD; 95%CI)
24.3 ± 4.77
(21.17–27.49)
Basal S100B
(mean ± SD; 95%CI)
0.0548 ± 0.0167
(0.0485–0.0611)
2 h S100B
(mean ± SD; 95%CI)
0.0617 ± 0.0217
(0.054–0.0695)
12 h S100B
(mean ± SD; 95%CI)
0.0686 ± 0.0321
(0.0585–0.0786)
24 h S100B
(mean ± SD; 95%CI)
0.0785 ± 0.0442
(0.0649–0.0921)
48 h S100B
(mean ± SD; 95%CI)
0.09 ± 0.0617
(0.0719–0.108)
Basal NSE
(mean ± SD; 95%CI)
6.18 ± 1.87
(5.49–6.85)
2 h NSE
(mean ± SD; 95%CI)
6.46 ± 1.75
(5.82–7.09)
12 h NSE
(mean ± SD; 95%CI)
6.39 ± 1.53
(5.75–7.02)
24 h NSE
(mean ± SD; 95%CI)
6.07 ± 1.67
(5.47–6.66)
48 h NSE
(mean ± SD; 95%CI)
5.86 ± 1.78
(5.22–6.50)
Increased S100B (n;%)* 22 (75.8%)
48 h increased S100B (n;%)° 26 (89.6%)
Increased NSE (n;%)* 11 (37.9%)
48 h increased NSE (n;%)° 13 (44.8%)
h: hour; DWMRI: diffusion-weighted magnetic resonance cerebral imaging; pt.: patient; MMS
Neuron-Specific Enolase;*: in every patient variations of S100B andNSEhave been analyzed com
to “increased”, “stable”, or “decreased” category if a ≥25% variation was detected and neurobiom
S100B andNSEhave been analyzed comparing the 48-hour valuewith the basal one so that ever
a ≥25% variation was detected and neurobiomarker values have been analyzed as categorical virrespective of lesion site (p = 0.007 and p = 0.03 for MMSE and
MoCA, respectively; Fig. 2).
Neurobiomarker values and variationswere not significantly different
between the two treatment groups at continuous and categorical analysis
(Table 3).Wallstent P
(OR; 95%CI)
7 (24.1%) 0.55
(1.41; 0.44–4.50)
3.43 ± 1.81
(1.72–5.13)
0.91
3.56 ± 1.07
(2.87–4.25)
0.49
27.9 ± 2.96
(26.16–29.56)
1
27.3 ± 1.7
(26.17–28.46)
0.53
22.4 ± 3.57
(19.42–25.47)
0.83
25.3 ± 4.11
(22.17–28.49)
0.64
0.0529 ± 0.0172
(0.0466–0.0592)
0.68
0.0605 ± 0.02
(0.0528–0.0683)
0.83
0.0657 ± 0.0206
(0.0557–0.0758)
0.69
0.071 ± 0.0265
(0.0575–0.0846)
0.44
0.082 ± 0.0302
(0.0639–0.1001)
0.53
5.86 ± 1.78
(5.18–6.54)
0.52
6.41 ± 1.67
(5.77–7.04)
0.9
6.18 ± 1.87
(5.54–6.81)
0.64
6.39 ± 1.53
(5.79–6-98)
0.45
6.07 ± 1.67
(5.42–6.71)
0.65
21 (72.4%) 0.76
(1.19; 0.36–3.88)
21 (72.4%) 0.09
(3.3; 0.77–14.02)
9 (31%) 0.58
(1.35; 0.45–4.02)
15 (51.7%) 0.59
(0.75; 0.27–2.12)
E: Mini-Mental State Examination Test; MoCA: Montreal Cognitive Assessment Test; NSE:
paring every valuewith the basal one so that every patient has been classified as belonging
arker values have been analyzed as categorical variables; °: in every patient variations of
y patient has been classified as belonging to “increased”, “stable”, or “decreased” category if
ariables.
Fig. 2. 3PCAS postoperative MMSE andMoCA scores: NPTs postoperative scores showed a
significant association with the presence of N5 DWMRI lesions, irrespective of lesion side
(p = 0.007 and p = 0.03 for MMSE and MoCA, respectively).
152 L. Capoccia et al. / International Journal of Cardiology 279 (2019) 148–153S100B values doubled at 48 h postoperatively in 24 patients; among
them 12 presented new DWMRI lesions; 48-h S100B increase was
significantly related to 72-h DWMRI lesions (p = 0.012; Fig. 3).
One inguinal haematoma was recorded in each treatment group.
One AMI occurred in CGuard patients.
4. Discussion
The newCGuard carotid stents have demonstrated a reduction in the
post-procedural embolic effect during the carotid plaque healing period
(considered as lasting up to 28–30 days after stent placement), with
plaque coverage as small as 165 μm [11,12,26]. In contrast, in the
present series there was no difference between the two stent groups
during the peri-procedural period.
According to our study, a not-negligible number of bilateral or
contralateral lesions were detected in both Wallstent and CGuard
stent groups. Some authors [27] have demonstrated that during the
procedure of CAS there are a high number of insulting maneuvers that
are on average performed into the arch whenever a transfemoral CAS
procedure is done. Aortic arch atherosclerotic disease is usually
preoperatively evaluated by CT scans so that very “shaggy” aortas are
commonly a reason to consider a different approach to the carotid
bifurcation. In our study all patients were submitted to aortic arch and
supraortic vessels CT evaluation to be enrolled for CAS, nevertheless
the images obtained are probably not sensitive enough to demonstrateFig. 3. 3PCAS postoperative lesions on DWMRI and S100B: analysis of basal and 48-hour
S100B values in patients with new postoperative lesions (DWMRI +) and in patients
without new postoperative lesions (DWMRI−).the capability of arch atherosclerosis to be affected by catheter andwire
passage andmovements that may dislodgemicroparticles to both brain
hemispheres. Data collected in the present study probably reflect what
happens into an arch commonly considered at low embolic risk when
crossed by a guidewire. However, an interesting study on association
between brain microemboli and clinical and subclinical consequences
has demonstrated that under 200 μm those particles can be considered
innocuous [28]. However, the possibility of embolism from the arch
should be properly evaluated [29], since it might not be prevented by
the use of CGuard vs Wallstent (nor other current carotid stent), not
even completely prevented from the intraprocedural use of EPDs,
nor eliminated from the flow-reversal systems with femoral access.
However, the use of flow-reversal protection systems may be consid-
ered safer during the procedure [30], while the use of cervical systems
might be considered protective fromperi-procedural arch plaque debris
detachments.
The Safety and Efficacy Study for Reverse Flow Used During Carotid
Artery Stenting Procedure (ROADSTER) multicenter trial published
results on the use of ENROUTE Trans-carotid NPS (Silk Road Medical
Inc., Sunnyvale, Calif), a transcarotid neuroprotection system that
warrants direct surgical common carotid access and cerebral embolic
protection with high-rate flow reversal in CAS [30]. The innovative
concept at the basis of this device is the possibility of applying a flow
reversal filter directly in the common carotid artery, thus allowing for
intraoperative debris to be averted from brain circulation, and avoiding
crossing the arch and dislodging arch microemboli in the early postop-
erative period.
To further support the hypothesis that the majority of microemboli
detected by our study are not from the carotid plaque, rather from
the main access vessel, namely the arch, studies on cervical access
employment during CAS – TCAR procedures – are extremely promising
because they have demonstrated the ability to keep the number of
embolic events to a minimum [8,30]. The possibility to combine com-
plete carotid plaque coverage by the use of amesh associated to a nitinol
skeleton stent, and to completely avoid going through the risky arch,
can be the future solution to reduce even themicroembolic brain conse-
quences. In our study the number of lesions was associated to both
increase in biomarkers levels and in decrease in NPTs scores. Those data
confirm previous studies concerning the effect of brain microembolic
burden on cognitive performance in the peri-procedural period [5].
The use of biomarkers dosage or NPTs in CAS should once again be
considered in major studies. The demonstration of extremely low major
complication rates in prospective studies [2,4,8,10–13,25,30–32] should
prompt the call for cognitive performance evaluation following any
carotid revascularization procedure [33–35].
5. Limitations
Despite its single-center nature, our study was able to provide the
same technique, procedure, and materials in all patients, except for
the kind of stent that was under investigation. This series represents
our preliminary experience with the new mesh-covered stent, in
contrast with the high experience gained in the use of Wallstent, so
that someminor technical obstacles can't be excluded in the evaluation
of results despite the adequate annual volume experience of the opera-
tors. Undoubtedly, clinical or subclinical relevance of peri-procedural
DW-MRI lesions requires further evaluation.
6. Conclusions
In our experience both CGuard and Wallstent stents showed an
acceptable rate of subclinical CAS-related neurological events with no
significant differences at 72-hour DWMRI between groups. The rate of
bilateral or contralateral lesions suggests that the peri-procedural
neurological damage may have extra-carotid sources.
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